# **ORIGINAL ARTICLE**



# **Alkaloids‑rich extracts from** *Cannabis sativa***,** *Datura stramonium***, and** *Nicotiana tabacum* **modulate sexual behavior and key enzymes relevant to sexual function in rats**

**Olamide W. Fasakin1  [·](http://orcid.org/0000-0002-1352-3252) Ganiyu Oboh1 · Ayokunle Olubode Ademosun1**

Received: 28 September 2021 / Accepted: 9 March 2022 / Published online: 23 March 2022 © The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature 2022

# **Abstract**

*Datura stramonium* and *Nicotiana tabacum* are plant-based psychoactive substances commonly employed as alternatives to the illicit plant, *Cannabis sativa*, during aphrodisiac concoction preparation. The present study compared the efect of illicit (*Cannabis sativa*) and licit (*Nicotiana tabacum* and *Datura stramonium*) psychoactive substances on sexual behavior and several biochemical parameters in the penile tissue of male rats. Alkaloid extracts were orally administered in doses of 5, 50, 500, and 2000 mg/kg bwt for 90 days. On day 90, behavioral studies were carried out, rats were sacrifced, penile tissues removed, and tissue homogenate prepared. Penile tissue homogenates were assayed for phosphodiesterase-5 (PDE-5), arginase, acetylcholinesterase, angiotensin-1 converting enzyme (ACE) and lactate dehydrogenase (LDH) activities, nitric oxide (NO), and reactive oxygen species (ROS) levels. Findings showed that alkaloid extracts of *Datura stramonium* reduced the mounting and intromission number, depleted the level of NO, increased the activities of PDE-5, arginase, ACE, and reduced AChE activities, while *Datura stramonium* and *Nicotiana tabacum* alkaloids increased ROS levels and inhibited the activity of LDH. In conclusion, the use of *N*. *tabacum* as an alternative to *C*. *sativa* during aphrodisiac concoction preparation may be justifed while *D*. *stramonium* inclusion may not be to mediate aphrodisiac efects.

**Keywords** *Cannabis sativa* · *Datura stramonium* · *Nicotiana tabacum* · Sexual function · Sexual behavior

# **Introduction**

Sexual function is a multifaceted action comprising of a complex interplay between the endocrine, vascular, and nervous systems as well as other biostructures that are essential for satisfactory sexual arousal, intercourse, and performance. Despite the importance of satisfactory sexual function to the normal male species, demanding living conditions, certain prescriptive and several nonprescriptive medications, change in lifestyle, pollution, dietary defciencies, and toxicants have negative efects on sexual life and result in sexual dysfunction (Chen et al. [2019](#page-9-0); Kenneth [2001\)](#page-10-0), with World Health Organization (WHO) listing sexual dysfunction as a major public health priority in both the rich and poor economic nations

 $\boxtimes$  Ganiyu Oboh goboh@futa.edu.ng; goboh2001@yahoo.com (WHO [2016\)](#page-10-1). This has triggered research to synthesize drugs, such as Alprostadil, Buspirone, Cyproheptadine, and Sildenafl, which have been implicated to have serious side effects (Malviya et al. [2016\)](#page-10-2). In Nigeria, a variety of natural products comprising crude extracts and aphrodisiac concoctions from plants are employed as alternatives to the synthesized drugs to mediate sexual motivation, prolonged duration, improved desire, and alertness with most of the crude extracts and aphrodisiac concoctions made from psychoactive plants, such as *Cannabis sativa* (Bonini et al. [2018\)](#page-9-1).

Due to *C. sativa* been illicit in Nigeria, naturally available and licit psychoactive plants, *Datura stramonium* and *Nicotiana tabacum* are employed as alternatives for its traditional medicine and recreational usage. Their rates of prevalence are on the increase due to the diferent and new experi-ences they offer (Abdurahman et al. [2019;](#page-9-2) Dumbili [2020](#page-9-3)). Although, the use of crude extracts and aphrodisiac concoctions from these psychoactive plants for treatment and management of sexual dysfunction have been observed in folklore. There has been dearth of scientifc validation for the traditional claims of the plants to improve or deplete

Functional Foods, Nutraceuticals and Phytomedicine Unit, Department of Biochemistry, Federal University of Technology, P.M.B. 704, Akure 340001, Nigeria

sexual behavior and function during chronic exposure. Furthermore, the comparative efects between the illicit and licit substances to mediate sexual function or dysfunction in chronic studies are scarce.

Sexual behavior and function are initiated via sexual excitement, a process implicated to elevate nitric oxide (NO) release from endothelial cells and nervous terminations via nitric oxide synthase (NOs) action. Nitric oxide synthase (NOs) uses molecular oxygen and l-arginine as the substrate to trigger the release of NO, which then difuses across the localized cell membrane into smooth muscles to trigger guanylyl cyclase enzymatic activation. This process in turn catalyzes guanosine-5′-triphosphate (GTP) biotransformation into 3′-5′-cyclic guanosine monophosphate (cGMP), a second messenger. The production of cGMP results in cGMPdependent protein kinase (PKG) step activation, which in turn phosphorylates proteins that are crucial for relaxation. Consecutively, cGMP production also triggers intracellular calcium ion  $(Ca^{2+})$  concentrations reduction. Both post-cGMP production processes trigger arterial and trabecular smooth muscle relaxation, leading to arterial dilation, elevated blood flow to the penis, and a successive erection and stiffness of the penis (Masuku et al. [2020](#page-10-3)). However, inhibition feedback is induced by phosphodiesterase-5 (PDE-5) enzyme activity on the cGMP to induce penile detumescence and arteriolar vasoconstriction (Castela and Costa [2016\)](#page-9-4), a process if overactivated may result in reduced cGMP levels and subsequently sexual dysfunction. Therefore, the ability of a drug to suppress PDE-5 enzyme activity will improve cGMP levels as well as sexual function (Odubanjo et al. [2018\)](#page-10-4). More so, suppression of acetylcholinesterase (AChE) activity increases acetylcholine (ACh) concentrations at penis corpus cavernosum smooth muscle cells to induce relaxation at the muscle and increase penile tumescence by triggering endothelium NO production (Ojo et al. [2019\)](#page-10-5). The renin-angiotensin system (RAS) has also been observed to play key roles in sexual function (Masuku et al. [2020](#page-10-3)). Meanwhile, reactive oxygen species (ROS) production has been implicated to oxidize tetrahydrobiopterin  $(BH_4)$  (a substrate for NO synthesis) to dihydrobiopterin  $(BH<sub>2</sub>)$ , resulting in uncoupling of NOs, which in turn results in superoxide production instead of NO production, thus leading to decreased NO levels (Zhao et al. [2015](#page-10-6)). Another essential toxicity indicator in sexual function/dysfunction is lactate dehydrogenase (LDH), an oxidoreductase (XOR) enzyme that is released into the bloodstream by cells after tissue damage (Akintunde et al. [2015\)](#page-9-5). Several studies have evaluated the effects of the plants on sexual function but the present study will focus on comparing the abilities of the alkaloids-rich extracts from the plants to modulate sexual behavior and key enzymes relevant to sexual function in male Wister rats to justify their use as aphrodisiac agents.

# **Materials and methods**

# **Sample collection and preparation**

*Cannabis sativa* and *Nicotiana tabacum* leaves, and *Datura stramonium* seeds were obtained in towns of Akure South Local Government of Ondo State in Nigeria. The seeds of *D*. *stramonium* and leaves of *C*. *sativa* and *N*. *tabacum* were authenticated and identifed at the CERAD (Centre for Research and Development) unit of the Federal University of Technology, Akure, Nigeria. The seeds and leaves were cleansed from debris, stalks, and other unwanted materials, and were afterward powdered with an electric blender.

# **Chemicals and reagents**

Acetylthiocholine iodide, acetic acid, angiotensin-1 converting enzyme, methanol, estradiol benzoate, progesterone, hydrogen peroxide, l-arginine, Coomassie blue G, para-nitrophenyl phenylphosphonate (PNPPP), nitrate, and Ellman's reagent was obtained from Sigma Chemical Co, St. Louis, MO, USA; Organon Limited, Kolkata, India; and Cadilla Healthcare Limited, Daman, India. All reagents used were of analytical grade and the water used was distilled.

# **Preparation of alkaloid‑rich extracts**

Alkaloid-rich extracts were prepared of *Cannabis sativa* and *Nicotiana tabacum* leaves and *Datura stramonium* seeds according to the methods of Ademiluyi et al. ([2016](#page-9-6)).

# **Experimental protocol**

Sixty-fve (65) Wistar albino rats (male) weighing an average of  $203 \pm 10$  g were purchased from the Biochemistry department animal house in the Federal University of Technology, Akure, Nigeria. Their handling and use were approved by the Animal ethical committee, Centre for Research and Development (CERAD) of the Federal University of Technology, Akure with the ethical number FUTA/ETH/2020/016. Stainless steel cages were used to house the Wistar albino rats in a room where 12-h light/dark cycle, relative humidity (60–70%), and room temperature (25–27 °C) were maintained all through the timing of the experiment. The rats were acclimatized for 2 weeks, after which they were grouped with each group consisting of fve (5) rats randomly selected and housed in a cage. The animals were grouped and doses of extract selected according to the Organization for Economic Co-operation and Development (OECD) guideline (2001) as described by Patrick-Iwuanyanwu et al ([2010\)](#page-10-7) as follows:

Group 1 consisted of the normal control rats orally administered distilled water only.

Group 2 consisted of rats orally administered alkaloidrich extracts of *C*. *sativa* once daily at doses of 5 mg/ kg bwt.

Group 3 consisted of rats orally administered alkaloidrich extracts of *C*. *sativa* once daily at doses of 50 mg/ kg bwt.

Group 4 consisted of rats orally administered alkaloidrich extracts of *C*. *sativa* once daily at doses of 500 mg/ kg bwt.

Group 5 consisted of rats orally administered alkaloidrich extracts of *C*. *sativa* once daily at doses of 2000 mg/ kg bwt.

Group 6 consisted of rats orally administered alkaloidrich extracts of *D*. *stramonium* once daily at doses of 5 mg/kg bwt.

Group 7 consisted of rats orally administered alkaloidrich extracts of *D*. *stramonium* once daily at doses of 50 mg/kg bwt.

Group 8 consisted of rats orally administered alkaloidrich extracts of *D*. *stramonium* once daily at doses of 500 mg/kg bwt.

Group 9 consisted of rats orally administered alkaloidrich extracts of *D*. *stramonium* once daily at doses of 2000 mg/kg bwt.

Group 10 consisted of rats orally administered alkaloidrich extracts of *N*. *tabacum* once daily at doses of 5 mg/ kg bwt.

Group 11 consisted of rats orally administered alkaloidrich extracts of *N*. *tabacum* once daily at doses of 50 mg/ kg bwt.

Group 12 consisted of rats orally administered alkaloidrich extracts of *N*. *tabacum* once daily at doses of 500 mg/ kg bwt; and.

Group 13 consisted of rats orally administered alkaloid-rich extracts of *N*. *tabacum* once daily at doses of 2000 mg/kg bwt.

Experimental animals were administered the alkaloidrich extracts through oral gavage within the hours of 09:00 to 11:00. They were allowed free access to rat chow and water ad libitum and the experiment lasted for 90 days after acclimatization.

# **Sexual behavioral assessment**

On the 90th day of administration, alkaloid-treated male rats were each paired with estrous Wistar albino female rats to assess the sexual behavior of the alkaloid-treated male rats. The Female rats were induced to estrous by the administration of estradiol benzoate at a dose of 2 μg/kg body weight at 48 h and progesterone, 500 μg/kg body weight at 4 h respectively before the commencement of sexual behavioral studies. The sexual behavior was assessed using a plastic box  $(80\times60\times60$  cm) that is clear and appropriate for digital video recordings in a diferent room from the administration room for 30 min per session. The behavioral study was carried out during the early hours starting at 6:00 a.m. Parameters assessed for sexual behavior were mounting number and latency and intromission number and latency (Ademosun et al. [2019](#page-9-7); Guohua et al. [2009](#page-9-8)).

#### **Tissue homogenate preparation**

On the 91st day after commencement of experiment, alkaloidtreated male rats were anesthetized using mild diethyl ether. Alkaloid-treated male rats were sacrifced while the penile tissues were excised and washed quickly in a cold saline solution, after which they were homogenized in 0.1 M physiological bufer (pH 7.4) and centrifuged in a 10,000 g refrigerated centrifuge for 10 min. The supernatant was decanted and used for biochemical analyses.

### **Biochemical assays**

The total protein content of penile tissue homogenate was measured using Coomassie blue method with bovine serum albumin serving as the standard (Bradford [1976\)](#page-9-9). Nitric oxide (NO) level was measured using 2% VCl3 in 5% HCl, 0.1% *N*-(1-naphthyl) ethylenediamine dihydrochloride, and 2% sulfanilamide (in 5% HCl) while the reduction of nitrate to nitrite by  $\text{VCl}_3$  was measured to determine the levels of NO at 540 nm (Miranda et al. [2001\)](#page-10-8). The phosphodiesterase-5 activity was measured using *p*-nitrophenyl phenylphosphonate (5 mM) and 20 mM Tris buffer (pH 8.0), while the resultant *p*-nitrophenol produced was measured at 400 nm at intervals of 60, 120, 180, 240, and 300 s (Kelly and Butler [1977\)](#page-10-9). Arginase activity was measured using  $1.0$  mM Tris–HCl buffer (pH) containing  $1.0$  mM MnCl<sub>2</sub> and 0.1 M arginine solution. The reaction was terminated with 2.5 ml Ehrlich reagent (2.0 g of *p*-dimethylaminobenzaldehyde in 20 ml of absolute HCl) after 10 min of incubation at 37 °C and measured at 450 nm (Zhang et al. [2001\)](#page-10-10); acetylcholinesterase activity was measured using 5,5′-dithiobis (2-nitrobenzoic) acid (3.3 mM) prepared by 0.1 M bufer (pH 7.0) constituting of NaHCO<sub>3</sub>. AChE iodide served as the substrate for the assay while absorbance was measured at 412-nm at intervals of 30, 60, 90, 120, 150, and 180 s (Perry et al. [2000](#page-10-11)). Angiotensin-1 converting enzyme (ACE) was measured using HHL (hippuryl-l-histidyl l-leucine) as substrate while the resultant hippuric acid (Bz-Gly) was measured to determine the activity









of ACE at 228 nm (Cushman and Cheung [1971\)](#page-9-10). Reactive oxygen species (ROS) level was measured using *N*–*N*-diethyl-paraphenylenediamine (DEPPD) (6 mg/ml) and ferrous sulfate (4.37  $\mu$ M) prepared in 0.1 M sodium acetate (pH 4.8). H<sub>2</sub>O<sub>2</sub> production was used to measure ROS level at 505 nm (Hayashi et al. [2007](#page-9-11)). Lactate dehydrogenase activity was measured using a commercially available kit (Randox Laboratories UK) (Weisshaar [1975\)](#page-10-12).

# **Statistical analysis**

All data were analyzed GraphPad Prism version 8.0 for windows using one-way analysis of variance (ANOVA) followed by Duncan multiple tests. Data were expressed as mean±standard error of mean (SEM) of fve (5) rats per group.

# **Results**

Figure [1](#page-4-0) revealed the efects of alkaloid extracts of *Cannabis sativa*, *Datura stramonium*, and *Nicotiana tabacum* at varying doses (5, 50, 500, and 2000 mg/kg bwt) on the mounting number (1a), mounting latency (1b), intromission number (1c), and intromission latency (1d) in comparison to the normal control group. Typically, the administration of *C*. *sativa* significantly increased  $(p<sup>0.05</sup>)$  the mounting and intromission number at doses of 5 and 50 mg/kg bwt though a signifcant decline in mounting and intromission number was observed at higher doses of 500 and 2000 mg/kg bwt of *C*. *sativa.* Although similar trends were also observed with the alkaloid extracts of *N. tabacum* administration, the effects were not significantly different  $(p \text{ }^{\text{c}} 0.05)$  compared to the normal control group. However, results revealed that alkaloid extracts

<span id="page-4-0"></span>**Fig. 1 a** Mounting number. C5—orally administered alkaloid extracts ◂ of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5 orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/ kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50 orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500—orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM  $(n=5)$ . Bars with superscript # are significantly  $(p<0.05)$  from the normal control group. **b** C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50 orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500 orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$  SEM ( $n=5$ ). Bars with superscript # are significantly  $(p<0.05)$  from the normal control group. **c** C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50 orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500 orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM (*n*=5). Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group. **d** C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50 orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500 orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM ( $n=5$ ). Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

of *D*. *stramonium* significantly reduced ( $p \le 0.05$ ) the mounting and intromission number in a concentration-dependent manner compared to the normal control group. Furthermore, the efects of alkaloid extract of *C*. *sativa* and *N*. *tabacum* on mounting and intromission were observed to be biphasic while alkaloid extracts of *D*. *stramonium* were observed to significantly increase ( $p<sup>0.05</sup>$ ) the mounting and intromission latency in a concentration-dependent manner compared to the normal control group.

The result of the efects of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* at varying doses (5, 50, 500, and 2000 mg/kg bwt) on nitric oxide (NO) levels in normal rats is presented in Fig. [2.](#page-5-0) Results revealed that administration of *C*. *sativa* alkaloids at 5, 50, and 500 mg/kg bwt signifcantly (*p* ˂ 0.05) elevated the NO level in comparison with the normal control group. The most prominent effect of *C. sativa* was observed at 500 mg/kg bwt while a decline in trend was observed at 2000 mg/kg bwt *C*. *sativa* alkaloid administration. Additionally, a similar trend was observed with *N*. *tabacum* alkaloid administration, with the efects of *C*. *sativa* alkaloids posing a prominent NO level than that observed with *N*. *tabacum* alkaloids. However, *D*. *stramonium* alkaloids administration signifcantly (*p* ˂ 0.05) depleted the level of NO in a concentration-dependent manner, when compared to the normal control group.

Figure [3](#page-5-1) revealed the efects of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* at varying doses (5, 50, 500, and 2000 mg/kg bwt) on the activity of phosphodiesterase-5 (PDE-5) in normal rats. *C*. *sativa* alkaloids significantly reduced ( $p \leq 0.05$ ) the activities of PDE-5 in normal rats when compared to the normal control group. Meanwhile, *D*. *stramonium* alkaloids significantly  $(p \textless 0.05)$  increased the activities of PDE-5 in a concentration-dependent manner. However, reduction in PDE-5 activities was also observed with *N*. *tabacum* alkaloid administration while showing no signifcant level of diference  $(p^{\texttt{0}}0.05)$  in comparison to the normal control group.

*C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* at varying doses (5, 50, 500, and 2000 mg/kg bwt) also caused signifcant (*p* ˂ 0.05) efects on arginase activity in normal rats (Fig. [4](#page-6-0)). The activities of arginase were signifcantly reduced (*p* ˂ 0.05) in *C*. *sativa* and *N*. *tabacum* alkaloids treated groups in a concentration-dependent manner in comparison to the normal control group. Whereas, administration of *D*. *stramonium* alkaloid caused a signifcant  $(p<sup>0.05</sup>)$  increase in the activities of arginase in a concentrationdependent manner in comparison to the normal control group.

The result of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* administration at varying doses (5, 50, 500, and 2000 mg/kg bwt) on acetylcholinesterase (AChE) activity are presented in Fig. [5](#page-6-1). The activity of AChE was significantly  $(p<sup>0.05</sup>)$ reduced in normal rats at *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* administration in a concentration-dependent manner, with *D*. *stramonium* alkaloid posing the most prominent efect when compared to the normal control group.



<span id="page-5-0"></span>**Fig. 2** Nitric oxide level. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50 orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500 orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM ( $n=5$ ). Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

Figure [6](#page-7-0) showed that the activities of angiotensin-1 converting enzyme (ACE) were signifcantly (*p* ˂ 0.05) reduced in a concentration-dependent manner during chronic administration of *C*. *sativa* and *N*. *tabacum* at doses of 5, 50, and 500 mg/kg. However, the reduction pattern was absent at 2000 mg/kg bwt administration which showed a concomitant increase but lower than that observed in the normal control group. Interestingly, chronic administration of *D*. *stramonium* was observed to increase ACE activities in a concentration-dependent manner.

Figure [7](#page-7-1) reveals the efects of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* at varying doses (5, 50, 500, and 2000 mg/ kg bwt) on reactive oxygen species (ROS) levels in comparison with normal control rats. Administration of *C*. *sativa* alkaloid at 5 and 50 mg/kg bwt was observed to lower the level of ROS while higher doses of 500 and 2000 mg/kg bwt of the alkaloids signifcantly (*p* ˂ 0.05) elevated ROS level. However, *D*. *stramonium* and *N*. *tabacum* alkaloids administration signifcantly (*p* ˂ 0.05) increased ROS level in normal rats, with *D*. *stramonium* posing a higher level of ROS production.



<span id="page-5-1"></span>**Fig. 3** Phosphodiesterase-5 activity. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000 orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5 orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/ kg bwt; T500—orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM  $(n=5)$ . Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

The efects of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* at varying doses (5, 50, 500, and 2000 mg/kg bwt) on the activity of lactate dehydrogenase (LDH), a functional asthenospermia marker in rat testes, are shown in Fig. [8](#page-8-0). Administration of *C*. *sativa* alkaloids improved the activity of LDH at 5 and 50 mg/kg bwt doses, though dosages of 500 and 2000 mg/kg bwt showed inhibitory efects on LDH activities. Efects of *D*. *stramonium* and *N*. *tabacum* were revealed to inhibit significantly  $(p \text{ }^{\lt} 0.05)$  the activities of LDH. The fgure further revealed that the potency of *D*. *stramonium* alkaloids to inhibit LDH activities was higher in comparison to that expressed by *N*. *tabacum* and alkaloids.

# **Discussions**

As observed in the present study, mounting number, mounting latency, intromission number, and intromission latency were greatly altered by exposure to the diferent concentrations of *C*. *sativa*, *D*. *stramonium*, and *N*. *tabacum* alkaloids



<span id="page-6-0"></span>**Fig. 4** Arginase activity. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50 orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500 orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM ( $n=5$ ). Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

in comparison to the normal control group. Interestingly, the study revealed a curvilinear model of effect on sexual activities. This biphasic model of the efect of the alkaloids is consistent with other studies that observed that chronic administration of plant-based psychoactive substances improves sexual function at low doses while at high doses impairment of testosterone secretion and sperm production was observed (German et al. [2014](#page-9-12); Johnson et al. [2020\)](#page-9-13). At the lower doses of administration (5 and 50 mg/kg bwt), the alkaloid extracts tend to favorably infuence sexual activities but at higher doses of 500 and 2000 mg/kg bwt, the sexual activities were adversely afected with *C*. *sativa* having the least deterioration. The decreased mounting and intromission latencies observed at lower doses may indicate the potential of *C*. *sativa* and *N*. *tabacum* to enhance the sex desire and sexual behavior in sexual dysfunctional individuals (Outhoff [2009](#page-10-13)). The trend of compromised sexual behavior at higher doses of *C*. *sativa* and *N*. *tabacum* and decreased sexual activities in *D*. *stramonium* groups as observed in the present study could result from elevated arginase and PDE-5 activities



<span id="page-6-1"></span>**Fig. 5** Acetylcholinesterase activity. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/kg bwt; C5000 orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5 orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/ kg bwt; T500—orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM  $(n=5)$ . Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

which have been established to result in lower copulation and sexual dysfunction (Adefegha et al. [2021\)](#page-9-14).

Nitric oxide (NO) release is central to the initiation of activation of soluble guanylate cyclase, inhibition of vascular smooth muscle proliferation, smooth muscle cell relaxation, and maintenance of vascular endothelial cells, which leads to vasodilation and reduced intracellular calcium levels during sexual activities (Andersson [2011](#page-9-15)). Results from the present study showed that *C*. *sativa* and *N*. *tabacum* posed a signifcant curvilinear efect while *D*. *stramonium* showed a concentration-dependent reduction in NO level. The possible explanation may be that the *C*. *sativa* and *N*. *tabacum* alkaloids increased endothelial tissue NOs activity expression and/or inhibited NO elimination, thereby resulting in increased nitric oxide bioavailability (Sasatomi et al. [2008](#page-10-14)).

The frst-line of drugs endorsed by the United States of Food and Drug Administration (FDA) in the management and treatment of sexual dysfunction are drugs that can prevent the PDE-5 enzyme from depleting cGMP levels and impeding arterial blood flow, a process that results in



<span id="page-7-0"></span>**Fig. 6** Angiotensin-1 converting enzyme activity. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50 orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/ kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000 orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/ kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500—orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM ( $n=5$ ). Bars with superscript # are significantly  $(p<0.05)$  from the normal control group

vasodilation and corpus cavernosum tissue relaxation as well as prolonged penile erection and improved sexual function (Hatzimouratidis et al. [2016;](#page-9-16) Sommer and Schulze [2005](#page-10-15)). Interestingly, *C*. *sativa* and *N*. *tabacum* alkaloids inhibited the activities of PDE-5 while *D*. *stramonium* alkaloids upregulated the activities of the enzyme. The ability of *C*. *sativa* and *N*. *tabacum* alkaloids to inhibit PDE-5 may be one of the mechanisms employed by the plant alkaloids to improve mounting and intromission numbers as observed in the present study, as the inhibition of PDE-5 will reduce rapid hydrolysis of cGMP by PDE-5 and thereby, prolonged penile erection and improved sexual functions. Meanwhile, the dose-dependent increase in PDE-5 activity observed with *D*. *stramonium* administration may be due to disorder in the NO/cGMP pathway, a major factor in sexual dysfunction (Lugnier [2006](#page-10-16)).

Another key mediator of reduced NO production during sexual activity is elevated arginase activity as observed in the present study. Whenever the activity of arginase is elevated, hydrolysis of L-arginine to urea and ornithine is increased via urea cycle, while the bioavailability and concentration of NO are depleted, due to NO synthase and arginase dependence



<span id="page-7-1"></span>**Fig. 7** Reactive oxygen species production level. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50 orally administered alkaloid extracts of *C. sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C*. *sativa* at 500 mg/ kg bwt; C5000—orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D*. *stramonium* at 5 mg/kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D*. *stramonium* at 500 mg/kg bwt; D5000 orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/ kg bwt; T5—orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/kg bwt; T500—orally administered alkaloid extracts of *N*. *tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N*. *tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM ( $n=5$ ). Bars with superscript # are significantly  $(p<0.05)$  from the normal control group

on the same substrate (*L*-arginine) (Caldwell et al. [2018](#page-9-17)). The present study observed that *C*. *sativa* and *N*. *tabacum* both decreased arginase activity signifcantly while *D*. *stramonium* increased arginase activity significantly. This may be the possible explanation for the effect of the alkaloids on NO release, as NO release is linked with an agent inhibitory effect on arginase activity (Lorenzen et al. [2009](#page-10-17); Adefegha et al. [2018](#page-9-18)). Although most sexual dysfunction management/treatment drugs are PDE-5 inhibitors and not arginase inhibitors, administration of PDE-5 inhibitors to manage/treat sexual dysfunction where arginase activity prevails is usually inefective. Therefore, the inhibitory efect of both *C*. *sativa* and *N*. *tabacum* alkaloid extracts on arginase activity may be another mechanism employed by the plants to improve the mounting and intromission number observed in the present study and further indicate their potential to improve sexual function as observed in folklore*.*

Acetylcholine (ACh), a parasympathetic neurotransmitter, mediates sexual function by relaxing the corpus cavernosum smooth muscle of the penis and enhances penile tumescence by triggering endothelial NO production (Ojo et al. [2019\)](#page-10-5). Therefore, the ability of a drug to inhibit the



<span id="page-8-0"></span>**Fig. 8** Lactate dehydrogenase activity. C5—orally administered alkaloid extracts of *C*. *sativa* at 5 mg/kg bwt; C50—orally administered alkaloid extracts of *C*. *sativa* at 50 mg/kg bwt; C500—orally administered alkaloid extracts of *C. sativa* at 500 mg/kg bwt; C5000 orally administered alkaloid extracts of *C*. *sativa* at 5000 mg/kg bwt; D5—orally administered alkaloid extracts of *D. stramonium* at 5 mg/kg bwt; D50—orally administered alkaloid extracts of *D*. *stramonium* at 50 mg/kg bwt; D500—orally administered alkaloid extracts of *D. stramonium* at 500 mg/kg bwt; D5000—orally administered alkaloid extracts of *D*. *stramonium* at 5000 mg/kg bwt; T5 orally administered alkaloid extracts of *N*. *tabacum* at 5 mg/kg bwt; T50—orally administered alkaloid extracts of *N*. *tabacum* at 50 mg/ kg bwt; T500—orally administered alkaloid extracts of *N. tabacum* at 500 mg/kg bwt; T5000—orally administered alkaloid extracts of *N. tabacum* at 5000 mg/kg bwt. Results are expressed as mean $\pm$ SEM  $(n=5)$ . Bars with superscript # are significantly  $(p < 0.05)$  from the normal control group

activity of AChE, the enzyme that hydrolysis ACh to choline and acetate, will increase ACh levels and enhance penile erection (Heidelbaugh [2010](#page-9-19); Ojo et al. [2019](#page-10-5)). Interestingly, all the alkaloid extracts inhibited AChE activity signifcantly with *D*. *stramonium* showing the highest level of inhibition. This substantiates a previous study that implicated *D*. *stramonium* alkaloids (atropine, hyoscyamine, and scopolamine) as a potent cholinesterase inhibitor (Fasakin et al. [2021\)](#page-9-20).

Another pathway that has also been implicated in sexual function/dysfunction pathophysiology is the renin-angiotensin system (RAS) pathway (Odubanjo et al. [2018\)](#page-10-4). The enzyme angiotensin-1 converting enzyme (ACE) is the enzyme tasked with catalyzing angiotensin-1 conversion to the potent angiotensin-2, the main constituent of the renin-angiotensin system (RAS), which mediates stimulated contraction of the corpus cavernosum smooth muscles during sexual functions (Fraga-Silva et al. [2013;](#page-9-21) Oboh et al. [2017\)](#page-10-18). Therefore, the high activities of ACE observed with *D*. *stramonium* administration may result in chronic high levels of angiotensin-2 which have been implicated to result in angiotensin type-1 receptor  $(AT<sub>1</sub>R)$  activation, leading to stimulation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase

and vasoconstriction, which results into excessive superoxide anions generation, depleted endothelial nitric oxide concentration, and sexual dysfunction (Ademiluyi et al. [2019](#page-9-22); Jiménez et al. [2019](#page-9-23); Passaglia et al. [2015;](#page-10-19) Rincón et al. [2015\)](#page-10-20). However, the reduction in ACE activities observed during *C*. *sativa* and *N*. *tabacum* administration may suggest their ability to act as ACE inhibitors at the dosages.

Furthermore, the present study observed that the alkaloid extracts elevated ROS production in a concentration-dependent manner, with signifcant levels of increase observed mostly at 500 and 2000 mg/kg bwt. The study also observed that *D*. *stramonium* had the highest level of ROS production. The elevation of ROS level has been linked with angiotensin-2 production (Adefegha et al. [2018\)](#page-9-18), a process that was also observed in the present study. Meanwhile, elevated ROS have been implicated to react with NO to produce peroxynitrite (ONOO– ) which decreases the bioavailability and concentration of NO (Zhao et al. [2015](#page-10-6)). Furthermore, the resulting peroxynitrite was implicated to cause the generation of powerful oxidants such as nitrogen dioxide  $(NO<sub>2</sub>)$  and hydroxyl radicals which result in oxidative stress and consecutively, sexual dysfunction (Tabit et al. [2010](#page-10-21)).

LDH activity has been widely used in assessing cellular ATP levels during anaerobic conditions due to its stability (Akintunde et al. [2015](#page-9-5)). The present study observed that *C*. *sativa* had a curvilinear effect on the enzyme while *D*. *stramonium* and *N*. *tabacum* signifcantly reduced the enzyme activity. The inhibitory efect of *D*. *stramonium* and *N*. *tabacum*, and *C*. *sativa* only at high doses on LDH activity can indicate an alteration to the metabolic pathway responsible for energy (ATP) production. The fnding agrees with previous studies that observed abnormal spermatogenesis and sexual dysfunction in link with depleted ATP levels (Klaassen and Watkins [2003](#page-10-22); Akintunde et al. [2015](#page-9-5)), an indication that only *C*. *sativa* alkaloids at doses of 5 and 50 mg/kg bwt may have potential to ameliorate depleted ATP levels in sexual dysfunctional individuals.

# **Conclusions**

Although, the relationship between psychoactive plant alkaloids and sexual function may be complex, the effect of the alkaloids on sexual behavior and key enzymes relevant to sexual function may proffer us mechanisms of action to justify their use in folklore as crude extracts or ingredients of aphrodisiac concoctions. According to our results, *C*. *sativa* and *N*. *tabacum* showed signifcant potency to improve sexual function (especially at 5 and 50 mg/kg bwt) while *D*. *stramonium* showed signifcant potency to facilitate sexual dysfunction across all doses during chronic exposure*.* This is an indication that the use of *D*. *stramonium* as ingredients of aphrodisiac concoctions may be to elevate the concoction's psychoactive efects and not majorly to improve the aphrodisiac potentials of the concoction. However, the use of *C*. *sativa* and *N*. *tabacum* crude extracts and as aphrodisiac concoction ingredients in folklore may be justifed but should be discouraged as its administration at high doses was observed to pose toxicological effects that may result in sexual dysfunction and even cause hazardous efects to users. Furthermore, molecular and clinical studies, as well as chemical identifcation and isolation of the bioactive compounds of these psychoactive plants, are recommended to evaluate their pharmacokinetic, pharmacodynamic, and toxicological mechanism of action to mediate the observed sexual function or dysfunction.

#### **Funding** None.

# **Declarations**

**Ethics approval** The care and use of Laboratory Animals were approved by the Federal University of Technology Akure ethical committee, which was followed strictly and in compliance with the National Institute of Health guidelines. Ethical approval was obtained from the Centre for Research and Development (CERAD), Federal University of Technology, Akure with the number FUTA/ETH/2020/016.

**Informed consent** All the authors contributed substantially to the work, participated in the writing, and have seen and approved the submitted version.

**Conflict of interest** The authors declare no confict of interest.

# **References**

- <span id="page-9-2"></span>Abdurahman H, Adejumo O, Abdulmalik J (2019) Prevalence of psychoactive substance use among male adolescents in Southwest Nigeria. J Subst Abus 24(5):475–480. [https://doi.org/10.1080/](https://doi.org/10.1080/14659891.2019.1604840) [14659891.2019.1604840](https://doi.org/10.1080/14659891.2019.1604840)
- <span id="page-9-14"></span>Adefegha SA, Oboh G, Olopade EO (2021) β-caryophyllene improves sexual performance via modulation of crucial enzymes relevant to erectile dysfunction in rats. Toxicol Res 37(2):249–260. [https://](https://doi.org/10.1007/s43188-020-00061-2) [doi.org/10.1007/s43188-020-00061-2](https://doi.org/10.1007/s43188-020-00061-2)
- <span id="page-9-18"></span>Adefegha SA, Oboh G, Fakunle B, Oyeleye SI, Olasehinde TA (2018) Quercetin, rutin, and their combinations modulate penile phosphodiesterase-5′, arginase, acetylcholinesterase, and angiotensin-I-converting enzyme activities: a comparative study. Comp Clin Pathol 27(3):773–780. <https://doi.org/10.1007/s00580-018-2664-y>
- <span id="page-9-6"></span>Ademiluyi AO, Ogunsuyi OB, Oboh G, Agbebi OJ (2016) Jimson weed (*Datura stramonium* L.) alkaloid extracts modulate cholinesterase and monoamine oxidase activities *in vitro*: possible modulatory efect on neuronal function. Comp Clin Pathol 25(4):733–741. <https://doi.org/10.1007/s00580-016-2257-6>
- <span id="page-9-22"></span>Ademiluyi AO, Oyeniran OH, Jimoh TO, Oboh G, Boligon AA (2019) Fluted pumpkin (*Telfairia occidentalis*) seed modulates some markers of erectile function in isolated rat's corpus cavernosum: infuence of polyphenol and amino acid constituents. J Food Biochem 43(11):1–11
- <span id="page-9-7"></span>Ademosun AO, Adebayo AA, Oboh G (2019) *Anogeissus leiocarpus* attenuates paroxetine-induced erectile dysfunction in male rats via enhanced sexual behavior, nitric oxide, and antioxidant status. Biomed Pharmacother 111:1029–1035
- <span id="page-9-5"></span>Akintunde JK, Oboh G, Akindahunsi AA (2015) Inhibition of key markers linked with spermatogenesis and cellular ATP by sub chronic exposure to leachate in a rat model. Arch Environ Contam Toxicol 68(1):159–168. <https://doi.org/10.1007/s00244-014-0068-9>
- <span id="page-9-15"></span>Andersson KE (2011) Mechanisms of penile erection and basis for pharmacological treatment of erectile dysfunction. Pharmacol Rev 63:811–859
- <span id="page-9-1"></span>Bonini SA, Premoli M, Tambaro S, Kumar A, Maccarinelli G, Memo M, Mastinu A (2018) *Cannabis sativa*: a comprehensive ethnopharmacological review of a medicinal plant with a long history. J Ethnopharmacol 227:300–315
- <span id="page-9-9"></span>Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254. [https://doi.org/](https://doi.org/10.1016/0003-2697(76)90527-3) [10.1016/0003-2697\(76\)90527-3](https://doi.org/10.1016/0003-2697(76)90527-3)
- <span id="page-9-17"></span>Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB (2018) Arginase: a multifaceted enzyme important in health and disease. Physiol Rev 98(2):641–665
- <span id="page-9-4"></span>Castela Â, Costa C (2016) Molecular mechanisms associated with diabetic endothelial erectile dysfunction. Nat Rev Urol 13(5):266–274
- <span id="page-9-0"></span>Chen L, Shi G, Huang D, Li Y, Ma C, Shi M, Su B, Shi G (2019) Male sexual dysfunction: a review of literature on its pathological mechanisms, potential risk factors, and herbal drug intervention. Biomed Pharmacother 112:108585. [https://doi.org/10.1016/j.](https://doi.org/10.1016/j.biopha.2019.01.046) [biopha.2019.01.046](https://doi.org/10.1016/j.biopha.2019.01.046)
- <span id="page-9-10"></span>Cushman DW, Cheung HS (1971) Spectrophotometric assay and properties of the angiotensin-converting enzyme of rabbit lung. Biochem Pharmacol 20(7):1637–1648
- <span id="page-9-3"></span>Dumbili EW (2020) Drug-related harms among young adults in Nigeria: implications for intervention. J Hum Behav Soc Environ 30(8):1013–1029.<https://doi.org/10.1080/10911359.2020.1790462>
- <span id="page-9-20"></span>Fasakin OW, Oboh G, Ademosun AO (2021) Neuromodulatory evaluation of commonly abused plants ex vivo: a comparative study. Comp Clin Pathol 30:671–680. [https://doi.org/10.1007/](https://doi.org/10.1007/s00580-021-03259-4) [s00580-021-03259-4](https://doi.org/10.1007/s00580-021-03259-4)
- <span id="page-9-21"></span>Fraga-Silva RA, Montecucco F, Mach F, Santos RAS, Stergiopulos N (2013) Pathophysiological role of the renin-angiotensin system on erectile dysfunction. Eur J Clin Invest 43(9):978–985
- <span id="page-9-12"></span>German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97:2–8
- <span id="page-9-8"></span>Guohua H, Yanhua L, Rengang M, Dongzhi W, Zhengzhi M, Hua Z (2009) Aphrodisiac properties of Allium tuberosum seeds extract. J Ethnopharmacol 122:579–582
- <span id="page-9-16"></span>Hatzimouratidis K, Salonia A, Adaikan G, Buvat, J, Carrier S, El-Meliegy A, McCullough A, Torres LO, Khera M (2016) Pharmacotherapy for erectile dysfunction: recommendations from the Fourth International Consultation for Sexual Medicine (ICSM 2015) J Sex Med 13(4):465–488
- <span id="page-9-11"></span>Hayashi I, Morishita Y, Imai K, Nakamura M, Nakachi K, Hayashi T (2007) High-throughput spectrophotometric assay of reactive oxygen species in serum. Mutat Res Genet Toxicol Environ Mutagen 631(1):55–61
- <span id="page-9-19"></span>Heidelbaugh JJ (2010) Management of erectile dysfunction. Am Fam Physician 81(3):305–312
- <span id="page-9-23"></span>Jiménez DL, Chozas JML, Montoro AE, Corral MÁR, Guerra LC, González JPM (2019) Could renin-angiotensin-aldosterone system activation explain the amputations associated with canaglifozin? The nitric oxide hypothesis. Diabetes Res Clin Pract 148:10–13
- <span id="page-9-13"></span>Johnson LE, Balyan L, Magdalany A, Saeed F, Salinas R, Wallace S, Veltri CA, Swogger MT, Walsh Z, Grundmann O (2020) The

potential for kratom as an antidepressant and antipsychotic. Yale J Biol Med 93:283–289

- <span id="page-10-9"></span>Kelly SJ, Butler LG (1977) Enzymic hydrolysis of phosphonateesters. Reaction mechanism of intestinal 50-nucleotide phosphodiesterase. Biochemistry 16:1102–1104
- <span id="page-10-0"></span>Kenneth LB (2001) Principles and practice of endocrinology and metabolism, 3rd edn. Williams & Wilkins, Lippincott, Philadelphia, p 957
- <span id="page-10-22"></span>Klaassen C, Watkins J (2003) Casarett and Doull's essentials of toxicology. McGraw-Hill, New York, p 512
- <span id="page-10-17"></span>Lorenzen JM, Ückert S, Scheller F, Haller H, Kuczyk MA (2009) Efects of arginase inhibitors on the contractile and relaxant responses of isolated human penile erectile tissue. World J Urol 27:805–810
- <span id="page-10-16"></span>Lugnier C (2006) Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specifc therapeutic agents. Pharmacol Ther 109:366–398
- <span id="page-10-2"></span>Malviya N, Malviya S, Jain S, Vyas S (2016) A review of the potential of medicinal plants in the management and treatment of male sexual dysfunction. Andrologia 48:880–893. [https://doi.org/10.](https://doi.org/10.1111/and.12677) [1111/and.12677](https://doi.org/10.1111/and.12677)
- <span id="page-10-3"></span>Masuku NP, Unuofn JO, Lebelo SL (2020) Promising role of medicinal plants in the regulation and management of male erectile dysfunction. Biomed Pharmacother 130:110555. [https://doi.org/10.](https://doi.org/10.1016/j.biopha.2020.110555) [1016/j.biopha.2020.110555](https://doi.org/10.1016/j.biopha.2020.110555)
- <span id="page-10-8"></span>Miranda KM, Espay MG, Wink DA (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide: Biol Chem 5:62–71
- <span id="page-10-5"></span>Ojo OA, Ojo AB, Oyinloye BE, Ajiboye BO, Anifowose OO, Akawa A, Olaiya OE, Olasehinde OR, Kappo AP (2019) *Ocimum gratissimum* Linn. Leaves reduce the key enzymes activities relevant to erectile dysfunction in isolated penile and testicular tissues of rats. BMC Complement Med Ther 19(71):1–10. [https://doi.org/](https://doi.org/10.1186/s12906-019-2481-0) [10.1186/s12906-019-2481-0](https://doi.org/10.1186/s12906-019-2481-0)
- <span id="page-10-18"></span>Oboh G, Ademiluyi AO, Oyeleye SI, Olasehinde TA, Boligon AA (2017) Modulation of some markers of erectile dysfunction and malonaldehyde levels in isolated rat penile tissue with unripe and ripe plantain peels: Identifcation of the constituents of the plants using HPLC. Pharm Biol 51(1):1920–1926
- <span id="page-10-4"></span>Odubanjo VO, Olasehinde TA, Oyeleye SI, Oboh G, Boligon AA (2018) Seed extracts from *Myristica fragrans* (Nutmeg) and *Moringa oleifera* (Drumstick tree) inhibits enzymes relevant to erectile dysfunction and metal-induced oxidative damage in rats' penile tissues. J Food Biochem 42(1):1–9. [https://doi.org/10.1111/](https://doi.org/10.1111/jfbc.12452) [jfbc.12452](https://doi.org/10.1111/jfbc.12452)
- <span id="page-10-13"></span>Outhoff K (2009) Antidepressant-induced sexual dysfunction. South Afr Fam Pract 51:298–302
- <span id="page-10-19"></span>Passaglia P, Ceron CS, Mecawi AS, Antunes-Rodrigues J, Coelho EB, Tirapelli CR (2015) Angiotensin type 1 receptor mediates chronic ethanol consumption-induced hypertension and vascular oxidative stress. Vascul Pharmacol 74:49–59
- <span id="page-10-7"></span>Patrick-Iwuanyanwu KC, Onyeike EN, Wegwu MO (2010) Hepatoprotective efects of methanolic extract and fractions of African mistletoe Tapinanthus bangwensis (*engl. k. krause*) from Nigeria. EXCLI J 9:187–194
- <span id="page-10-11"></span>Perry NS, Houghton PJ, Theobald A, Jenner P, Perry EK (2000) Invitro inhibition of human erythrocyte acetylcholinesterase by *Salvia lavandulaefolia* essential oil and constituent terpenes. J Pharm Pharmacol 52(7):895–902
- <span id="page-10-20"></span>Rincón J, Correia D, Arcaya JL, Finol E, Fernández A, Pérez M, Yaguas K, Talavera E, Chávez M, Summer R, Romero F (2015) Role of Angiotensin II type 1 receptor on renal NAD (P) H oxidase, oxidative stress and infammation in nitric oxide inhibition induced-hypertension. Life Sci 124:81–90
- <span id="page-10-14"></span>Sasatomi K, Hiragata S, Miyazato M, Chancellor BM, Morris S, Yoshimura N (2008) Nitric oxide mediated suppression of detrusor overactivity by arginase inhibitor in rats with chronic spinal cord injury. Urology 72:696–700
- <span id="page-10-15"></span>Sommer F, Schulze W (2005) Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 23:385–392
- <span id="page-10-21"></span>Tabit CE, Chung WB, Hamburg NM, Vita JA (2010) Endothelial dysfunction in diabetes mellitus: Molecular mechanisms and clinical implications. Rev Endocr Metab Disord 11(1):61–74
- <span id="page-10-12"></span>Weisshaar HD (1975) Normal ranges of alpha-HBDH, LDH, AP, and LAP as measured with substrate-optimated test charges. Med Welt 26:387–392
- <span id="page-10-1"></span>World Health Organization (2016) Progress report 2016: prevent HIV, test and treat all: WHO support for country impact (No. WHO/ HIV/2016.24) Geneva: World Health Organization
- <span id="page-10-10"></span>Zhang C, Hein TW, Wang W, Chang CI, Kuo L (2001) Constitutive expression of arginase in microvascular endothelial cells counteracts nitric oxide mediated vasodilatory function. FASEB J 15:1264–1266
- <span id="page-10-6"></span>Zhao Y, Vanhoutte PM, Leung SWS (2015) Vascular nitric oxide: Beyond eNOS. J Pharmacol Sci 129(2):83–94

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.